[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-scarring-fibrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-scarring-fibrosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100627466","losartan-for-corneal-fibrosis-100627466",false,"NCT07449000","Losartan for Corneal Fibrosis","Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis","* Inclusion Criteria:\n\n  * Adults aged 18 years or older\n  * Presence of corneal scar with a duration of at least 1 month\n  * Corneal scars of any etiology\n  * Corneal scars with or without corneal neovascularization\n  * Stable corneal scar without epithelial defect\n  * No active treatment for the underlying condition for at least 1 month\n* Exclusion Criteria:\n\n  * Refusal or inability to provide written informed consent\n  * Presence of corneal epithelial defect or friable epithelium\n  * Age under 18 years\n  * Pregnancy\n  * Known allergy or hypersensitivity to losartan","ALL","18 Years",{"count":19,"type":20},46,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg\u002FmL or placebo eyedrops 6 times per day for six months.",[26],"Corneal Scarring Fibrosis",[28,29,30,31,32],"Corneal scar","Corneal scarring","Corneal haze","Corneal opacity","Topical losartan","RECRUITING","2026-05-04",{"date":36,"type":37},"2026-05-08","ACTUAL",{"date":39,"type":37},"2026-02-12",{"date":41,"type":20},"2027-03-01",{"name":43,"class":44},"Universidad Autonoma de Nuevo Leon","OTHER"]